Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | PF-07265807 |
Synonyms | |
Therapy Description |
PF-07265807 is a small molecule inhibitor of MERTK and AXL, which may modulate immune response and lead to anti-tumor activity (J Clin Oncol 39, 2021 (suppl 15; abstr TPS2671). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PF-07265807 | PF 07265807|PF07265807 | AXL Inhibitor 30 MERTK Inhibitor 13 | PF-07265807 is a small molecule inhibitor of MERTK and AXL, which may modulate immune response and lead to anti-tumor activity (J Clin Oncol 39, 2021 (suppl 15; abstr TPS2671). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04458259 | Phase I | PF-07265807 | A Study of PF-07265807 In Participants With Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | ITA | ESP | CAN | AUS | 3 |